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Objective: To determine the role of progressive ankylosis protein (ANK)/Myb-binding protein 1a
(MYBBP1a) and sphingosine kinase 1 (SPHK1) interactions in catabolic events of articular chondrocytes.
Method: ANK/MYBBP1a and SPHK1 interactions were identiﬁed using yeast two-hybrid screening and
co-immunoprecipitation. To determine the role of these interactions in catabolic events of articular
chondrocytes, ank/ank and wild type (WT) mouse chondrocytes transfected with full-length or mutant
ank expression vectors (EVs) or femoral heads were treated with interleukin-1beta (IL-1b) in the absence
or presence of SPHK inhibitor. Catabolic marker mRNA levels were analyzed by real time PCR; proteo-
glycan loss using safranin O staining and MMP-13 immunostaining were determined in femoral head
explants; NF-kB activity was determined by transfecting chondrocytes with an NF-kB-speciﬁc luciferase
reporter and analyzing nuclear translocation of p65 by immunoblotting; MYBBP1a nuclear or cyto-
plasmic amounts were determined by immunohistochemistry and immunoblotting.
Results: The ANK N-terminal region interacted with SPHK1, whereas a cytoplasmic C-terminal loop
interacted with MYBBP1a. Lack of ANK/MYBBP1a and SPHK1 interactions in ank/ank chondrocytes
resulted in increased MYBBP1a nuclear amounts and decreased SPHK1 activity, and consequently
decreased NF-kB activity, catabolic marker mRNA levels, proteoglycan loss, and MMP-13 immunostaining
in IL-1b-treated articular chondrocytes or femoral heads. Transfection with full-length ank EV reduced
nuclear MYBBP1a amounts and fully restored SPHK and NF-kB activities in IL-1b-treated ank/ank
chondrocytes, whereas transfection with P5L or F376del mutant ank reduced nuclear MYBBP1a or
increased SPHK activity, respectively, and consequently either transfection only partially restored NF-kB
activity.
Conclusion: ANK/MYBBP1a and SPHK1 interactions stimulate catabolic events in IL-1b-mediated carti-
lage degradation.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The progressive ankylosis protein (ANK) is a transmembrane
protein that transports intracellular pyrophosphate (PPi) to the
extracellular milieu1. Extracellular PPi has been shown to inhibit
basic calciumphosphate (BCP) crystal formation2. Lack of functional: T. Kirsch, Musculoskeletal
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gery, Brigham and Women’s
west Hospital, Third Military
ternational. Published by Elsevier LANK in ank/ank mice or ank knockout mice leads to pathological
mineralization of articular cartilage, ligaments,menisci and tendons
resulting in arthritic changes1,3. Several studies, however, including
those from our laboratory have shown that ANK is expressed at low
levels in healthy articular cartilage, and ANK expression levels
drastically increase during osteoarthritis (OA) initiation and pro-
gression4e6. Theseﬁndings raise the possibility that ANKplaysmore
complex and unknown functions in articular cartilage and OA pa-
thology than only preventing BCP crystal formation.
It has been suggested that ANK performs functions unrelated
to the PPi transport activity, and speciﬁcally interactions of ANK
with other intracellular proteins may alter the functions or activ-
ities of these proteins7. Furthermore, it was suggested that ANK
mutations leading to chondrocalcinosis, a disease characterized by
the formation of calcium pyrophosphate dihydrate crystals, and
ANK mutations leading to craniometaphyseal dysplasia (CMD)td. All rights reserved.
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contribute to disease pathology8e10.
We asked the question of how increased ANK expression in OA
cartilage affects articular chondrocytes. Speciﬁcally, we tested the
possibility that ANK interacts with proteins that affect NF-kappa(k)
B signaling. NF-kB is a central signaling pathway responsible for
catabolic events in articular chondrocytes in OA11. To determine
whether ANK affects NF-kB signaling and ultimately catabolic
events, we treated ank/ank and wild type (WT) chondrocytes or
femoral heads with interleukin-1b (IL-1b) and analyzed NF-kB ac-
tivity and the mRNA levels of catabolic markers. IL-1b is a major
activator of NF-kB in chondrocytes and plays a central role in
cartilage degradation during OA progression12.
Methods
Mice
The ank/ank breeding colony obtained form Jackson Laboratory
was on a hybrid background derived from crossing a C3H and
C57BL/6 hybrid male with a BALB/c female. Heterozygous breeders
were used to generate ank/ank and WT littermates, with geno-
types analyzed by polymerase chain reaction (PCR), as described
previously1. All protocols involving mice were approved by the
Institutional Animal Care and Use Committee at NYU School of
Medicine.
Cell cultures
Chondrocytes were isolated from articular cartilage of 5-day-
old ank/ank mice and WT littermates as described previously13.
Cells were plated at a density of 1  105/well into 6-well tissue
culture plates and grown in monolayer cultures in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Life Technologies, Grand Island,
NY) containing 10% fetal calf serum (FCS; HyClone, Logan, Utah),
2 mM L-glutamine (Life Technologies), and 50 U/ml of penicillin
and streptomycin (Life Technologies). Semiconﬂuent chondrocytes
were transfected with empty pcDNA expression vector (EV) or
pcDNA EV containing full-length ank, P5L mutant ank, or F376del
ank cDNA using X-tremeGENE HP DNA transfection reagent per
the manufacturer’s protocol (Roche, Branchburg, NJ). We used the
pcDNA vector, which contains a c-myc tag. We obtained a trans-
fection rate of w40e50% as determined by immunostaining of
transfected cells with FITC-labeled antibodies speciﬁc for c-Myc
(Abcam) and counterstaining of cell nuclei with 40,6-diamidino-2-
phenylindole (DAPI) (data not shown). Forty-eight hours after
transfection, chondrocyte cultures were switched to serum-free
medium for 24 h followed by treatment with 10 mM 4-[[4-(4-
chlorophenyl)-2-thiazolyl]amino]phenol (SKI-II, TOCRIS Biosci-
ence) and 10 ng/ml recombinant mouse IL-1b (R
_
D
_
Systems, Min-
neapolis, MN) in PBS/0.1% bovine serum albumin (BSA). Treatment
with SKI-II was started 1 h before IL-1b treatment. Control cultures
were treated with dimethyl sulfoxide (DMSO) and PBS/0.1% BSA
(vehicle). ank/ank and WT femoral heads were cultured in DMEM
in the absence or presence of 10 ng/ml recombinant mouse IL-1b
for 4 days.
Histology and immunohistochemistry
Femoral heads were ﬁxed in 4% paraformaldehyde, decalciﬁed
in 0.2 mol/l ethylene-diaminetetraacetic acid (EDTA), embedded in
parafﬁn, and 4-mm-thick sections were cut perpendicular to the
cartilage surface. Sections were stained with safranin O. Loss of
safranin O staining in IL-1b-treated femoral head explant cultures
was analyzed using the following arbitrary scale: 0, normal safraninO staining intensity; 1, reduced staining; 2, focal patchy loss of
staining; 3, 50% of cartilage without staining. Five sections from
each femoral head explant spacedw70 mm apart were scored. The
score for an individual joint consists of the summed values for these
sections. A total of 8 vehicle-treated and 8 IL-1b-treated femoral
heads from eight different mice in each group (ank/ank; WT) were
analyzed.
For immunohistochemistry, cells were ﬁxed with acetone and
methanol (1:1) for 10 min at 20C. Sections were incubated with
sheep testicular hyaluronidase (2 mg/ml; Sigma, St. Louis, MO) in
PBS, pH 7.5, for 30 min at 37C. Immunostaining for MMP-13 was
performed using the Histostain SP Kit (Zymed Laboratories Inc., San
Francisco, CA) following the manufacturer’s instructions. After in-
cubation with a blocking solution for 20 min at room temperature,
sections were incubated overnight at 4C with primary MMP-13-
speciﬁc antibodies (Abcam, Cambridge, MA) followed by bio-
tinylated secondary antibodies for 30 min at room temperature.
After washing, sections were incubated with a streptavidine
peroxidase conjugate for 60min at room temperature followed by a
solution containing diaminobenzidine (chromogen) and 0.03%
hydrogen peroxide for 3 min at room temperature. Control sections
were incubated with non-immune rabbit serum. Cells were incu-
bated with primary antibodies speciﬁc for MYBBP1a (Abcam) fol-
lowed by FITC-conjugated secondary antibodies (Life Technologies).
Nuclei were counterstained with DAPI. Fluorescent images were
acquired with an epiﬂuorescent microscope (Olympus IX71,
Olympus America, Inc., Center Valley, PA) and a digital charge-
coupled device (CCD) camera (ORCA-R2 C10600e10B; Hamamatsu
Corporation, Middlesex, NJ); the signal was collected as white light
and pseudo-colored to facilitate differentiation between FITC (green
pseudo-color) and DAPI (red pseudo-color) labeling using IPLab
3.6.5 software.
Luciferase reporter assays
Cells were co-transfected with a ﬁreﬂy NF-kB-speciﬁc lucif-
erase reporter vector (pNFkB-Met-Luc2-Reporter; Clontech Labo-
ratories Inc., Mountain View, CA). Luciferase activity in the
medium from the secreted Metridia luciferase reporter gene was
monitored using the Ready-To-Glow Secreted Luciferase Reporter
Assay (Clontech) and the Tristar LB 941 luminometer (Berthold
Technologies, Oak Ridge, TN). Transfection efﬁciency was moni-
tored by co-transfection with pSEAP vector (Clontech), which
provides constitutive expression of secreted form of human
placental alkaline phosphatase (SEAP). Secreted SEAP activity was
monitored with the chemiluminescent substrate CSPD. All
experiments were performed in triplicate and repeated three
times.
RT-PCR and real-time PCR analysis
Total RNA was isolated from chondrocyte cultures using the
RNeasy minikit (Qiagen, Valencia, CA). mRNA levels of ADAMTS-5,
Cox-2, IL-6, inducible nitric oxide synthase (iNOS), and MMP-13
were quantiﬁed by real-time PCR as described previously14.
Brieﬂy, 1 mg of total RNA was reverse transcribed by using an
Omniscript RT kit (Qiagen). A 1:100 dilution of the resulting cDNA
wasused as the template toquantify the relative content ofmRNAby
real-time PCR (StepOnePlus System; Life Technologies) with the
appropriate primers. The following primers were used: ADAMTS-5:
forward primer 30-CCTACCCAA AGCACAGAA AGTCA-50, reverse
primer 50-GCAGATTCT GCCCATAATTCG-30; Cox-2: forward primer
50-GCTTCGGGAGCACAACAGA-30, reverseprimer50-TGGTTTGGAATA
GTTGCTCATCA-30; IL-6: forward primer 30-CTCTGGGAAATCGTG
GAAATG-30, reverse primer 50-AAGTG CATCATCGTTGTTCATACA-30;
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primer: 50-CAACCCGA GCTCCTGGAA-30; MMP-13: forward primer
50-GATGAAGACCCCAACCCTAAGC-30, reverse primer 50-CTGGTA
ATGG CATCAA GGGATAG-30; 18S: forward primer 50-ACGAGACTC
TGGCATGCTAACTAGT-30, reverse primer 50-CGCCACTTGTCCCTCTAA
GAA-30. PCRs were performed with an SYBR Green PCR Master Mix
kit (Life Technologies), with 95C for 10min followed by 40 cycles at
95C for 15 s and 60C for 1min, and 1 cycle at 95C for 15 s and 60C
for1min. The18SRNAwasampliﬁedat the same timeandusedas an
internal control. Thequantiﬁcation cycle values (Cq) for 18SRNAand
the samples were measured and calculated by computer software.
Transcript levels were calculated as x ¼ 2eDDCq, in which DDCq is
DE e DC, DE ¼ Cqexp  Cq18S and DC ¼ Cqcrtl  Cq18S.Co-immunoprecipitation
Mouse articular chondrocyte cultures were extracted with a
buffer containing 50 mM Tris/HCl, pH 7.4, 1% Nonidet P-40, 0.1%
Triton X-100, 150 mM NaCl, 5 mM EDTA, and proteinase inhibitor
mixture. Cell lysates (1 mg of total protein) were incubated with
TrueBlot Anti-Rabbit Ig IP Beads (Rockland Immunochemicals Inc.,
Gilbertsville, PA) for 30 min at 4C to remove nonspeciﬁc protein
binding. The supernatants were then incubated with primary rab-
bit polyclonal ANK speciﬁc IgG or no primary antibody (control) for
2 h at 4C followed by incubationwith the TrueBlot Anti-Rabbit Ig
IP Beads for 2 h at 4C with rotation. After washing, the antibodye
antigen complexes were eluted from the beads by incubation with
30 ml NuPAGE sodium dodecyl sulfate (SDS) sample buffer con-
taining a reducing agent (Life Technologies) at 100C for 5 min, and
analyzed by electrophoresis in 10% bis-tris polyacrylamide gels.
Samples were electroblotted onto nitrocellulose ﬁlters after elec-
trophoresis. After blocking with a solution of 5% low-fat milk pro-
tein, blotted proteins were immunostained with primary
polyclonal rabbit antibodies speciﬁc for ANK or monoclonal mouse
anti-MYBBP1a (Cell Signaling Technology Inc., Danvers, MA),
SPHK1 (Cell Signaling Technology Inc.), or SPHK2 (Abcam) anti-
bodies followed by peroxidase-conjugated secondary rabbit
TrueBlot Anti-Rabbit IgG HRP. The signal was detected by
enhanced chemiluminescence (Pierce Protein Biology Products,
Rockford, IL) as described14. The production and speciﬁcity of the
polyclonal rabbit anti- ANK IgG were described by us previously4.MYBBP1a
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Fig. 1. ANK interacts with MYBBP1a and SPHK1 but not with SPHK2 as revealed by co-immu
Immunoprecipitation with ANK-speciﬁc antibodies (ANK) or no antibodies (Control); Immu
SPHK1-speciﬁc antibodies (SPHK1), SPHK2-speciﬁc antibodies (SPHK2), or ANK-speciﬁc antSubcellular fractionation
To extract the cytoplasmic, nuclear and plasma membrane
fractions from ank/ank and WT articular chondrocytes we used the
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce
Biology Products) following the manufacturer’s instructions. Thirty
mg of total cytoplasmic, nuclear or plasma membrane protein
fractions was analyzed by SDS polyacrylamide gel electrophoresis
(PAGE) and immunoblotting with antibodies speciﬁc for MYBBP1a,
NF-kB p65 (Cell Signaling Technology Inc.) or phosphorylated
SPHK1 (LifeSpan Biosciences Inc., Seattle, WA) as described above.
For normalization of the protein expression levels the membranes
were immunostained with antibodies speciﬁc for b-actin (cyto-
plasmic fraction, Cell Signaling Technology), lamin B (nuclear
fraction, Abcam), or ATP1A1 (plasma membrane fraction; Abcam).
Yeast two-hybrid (Y2H) library screen
Plasmid pDB-ank N-terminal fragment (aa. 1e100), pDB-ank-C-
terminal fragment (aa. 320e419), pDB-P5L mutant ank N-terminal
region, and pDB-F376del ank C-terminal regionwere used as bait to
screen the Y2H murine 10.5-day embryonic cDNA library (Invi-
trogen) according toamodiﬁedmanufacturer’s protocol. Brieﬂy, bait
plasmid was introduced into a yeast MAV203 strain that contained
three reporter genes, HISþ, URAþ, and lacZ (Life Technologies), and
transformants were selected on deﬁned medium lacking leucine.
Themurine cDNA library in the vector pPC86was then transformed
into the resultant Leuþ yeast strain and plated on medium lacking
tryptophan, leucine, histidine, and uracil but containing 25 mm 3-
amino-1,2,4-trizone that can speciﬁcally inhibit the activity of HIS3
gene product and block the basal concentration ofHIS3 in yeast (SD-
leu/trp/his/ura/3ATþ). After incubation for 7e10 days at 30C,
colonies were screened for b-galactosidase by a ﬁlter lift assay. In-
dividual pPC86 recombinant plasmids that were identiﬁed in the
initial screen were further veriﬁed for interaction with bait by
repeating the Y2H assay and analyzed by DNA sequencing.
SPHK activity
SPHK activity was measured using the Sphingosine Kinase Ac-
tivity Assay (Echelon Bioscience Inc., Salt Lake City, UT) as the
manufacturer instructed.B BL
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noprecipitation of these proteins from cell lysates of mouse articular chondrocytes. IP:
noblot (IB) of the immunoprecipitates with MYBBP1a-speciﬁc antibodies (MYBBP1a),
ibodies (ANK) (L, lysate; B, beads).
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The data are expressed as mean with 95% conﬁdence intervals
and were analyzed using one-way analysis of the variance
(ANOVA). When ANOVA showed signiﬁcant differences between
the groups, Tukey’s post hoc test was used to determine the pairs of
groups showing signiﬁcant differences. P value of <0.05 was
considered statistically signiﬁcant.
Results
ANK interacts with MYBBP1a and SPHK1
We performed an Y2H screen to identify proteins that bind to
the cytoplasmic N-terminal region of ANK containing most of the
chondrocalcinosis mutations and C-terminal cytoplasmic loop ofA MYBBP1a DAPI Merged
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Fig. 2. A: Immunostaining of WT and ank/ank mouse articular chondrocytes with antibodie
(WT), and ank/ank articular chondrocytes transfected with the empty (ank/ank), the full-len
with antibodies speciﬁc for MYBBP1a (MYBBP1a) followed by FITC-labeled secondary antibo
DAPI (DAPI; red pseudo-color). MYBBP1A and DAPI images were merged (Merged). Bar, 100
chondrocytes transfected with empty EV and ank/ank chondrocytes transfected with empty
with IL-1b (IL-1) for the time periods indicated with antibodies speciﬁc for MYBBP1a. The
lamin B, a nuclear protein, to control for equal loading in each fraction. Representative blot
the band intensities was measured using VisionWorksLS software (UVP, lLC, Upland, CA). Da
normalized values fromWT cells transfected with empty expression vector (EV WT) at time p
intensities from three independent blots using three different cell cultures for the WT and th
were analyzed using one-way ANOVA followed by Tukey’s post hoc test. P value means comANK containing most of the CMD mutations10,15. These regions
have been suggested to interact with other proteins7. We screened
w2.5 million clones and identiﬁed 11 yeast clones that activated
the reporter gene containing the N-terminal region of ANK and 12
clones that activated the reporter gene containing the C-terminal
loop of ANK (data not shown). One of the positive clones that
activated the reporter gene containing the N-terminal region of
ANK encoded for SPHK1, and one of the positive clones that
activated the reporter gene containing the C-terminal loop
encoded for MYBBP1a. SPHK1 and MYBBP1a, however, were not
identiﬁed to interact with the P5L mutated N-terminal region
or the F376del C-terminal loop of ANK, respectively (data not
shown).
To verify these interactions, co-immunoprecipitation experi-
ments were performed using cell lysates from mouse articular
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ments revealed that MYBBP1a and SPHK1 but not SPHK2 co-
immunoprecipitated with ANK indicating interactions between
ANK and MYBBP1a, and ANK and SPHK1 [Fig. 1].
Loss of ANK function resulted in increased amounts of nuclear
MYBBP1a
Nuclear MYBBP1a has been recently shown to bind to the DNA
bound p50/p65 NF-kB complex and to repress its transcriptional
activity16. To test the hypothesis that the binding of MYBBP1a to
ANK prevents the nuclear translocation of MYBBP1a, we performed
immunolocalization studies of MYBBP1a using WT and ank/ank
articular chondrocyte cultures and immunostaining of these cellsWT
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stainedwith DAPI. Whereas most MYBBP1a immunostaining inWT
chondrocytes was localized in the cytoplasm, most of the immu-
nostaining for MYBBP1a in ank/ank chondrocytes was localized in
the nucleus, suggesting that loss of ANK results in nuclear trans-
location of MYBBP1a [Fig. 2(A)]. Transfection of ank/ank chon-
drocytes with an EV containing full-length ank cDNA (ank) or the
P5L mutant ank (P5L), which both interact with MYBBP1a, resulted
in cytoplasmic immunostaining for MYBBP1a and loss of nuclear
MYBBP1a immunostaining, whereas transfection of ank/ank chon-
drocytes with an EV containing F376del ank (F376del) that does not
interact with MYBBP1a resulted in similar nuclear MYBBP1a im-
munostaining as in empty vector transfected ank/ank chondrocytes
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Fig. 4. NF-kB activity as determined by the luciferase activity from an NF-kB luciferase
reporter inWTarticular chondrocytes (WT) transfectedwith empty (EV) or ank (ank) EV,
and ank/ank chondrocytes (ank/ank) transfected with empty (EV), ank (ank), P5L,
or F376del EV in the absence (IL-1) or presence (þIL-1) of IL-1b. Chondrocytes were
co-transfected with the pNFkB-Met-Luc2-luciferase reporter and the various ank EVs or
an empty vector control (EV). After transfection cells were serum-starved for 24 h and
then cultured in the presence of vehicle or IL-1b for 6 h. Transfection efﬁciency was
monitored byco-transfectionwith pSEAP vector,which provides constitutive expression
of secreted formof humanplacental alkaline phosphatase (SEAP). Secreted SEAP activity
was monitored with the chemiluminescence substrate CSPD. The results represent the
mean with 95% CI (three independent cell cultures for the WT and the ank/ank group;
onemouse per groupwas used to isolate cells for one culture). Datawere analyzed using
one-way ANOVA followed by Tukey’s post hoc test. P value means comparing with
indicated group.
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MYBBP1a after IL-1b treatment, we serum-starved WT transfected
with an empty EV and ank/ank articular chondrocytes transfected
with an empty EV, or an EV containing ank, P5L or F376del for 48 h
followed by treatment of these cells with IL-1b. After IL-1b treat-
ment, nuclear and cytoplasmic extracts from these cell cultures
were analyzed by immunoblotting with MYBBP1a-speciﬁc anti-
bodies. The amount of nuclear MYBBP1awas markedly increased in
ank/ank chondrocytes compared to WT chondrocytes, whereas the
amount of cytoplasmic MYBBP1a was decreased [Fig. 2(B), (C)].
Transfection of ank/ank chondrocytes with ank or P5L, which
interact with MYBBP1a, decreased the amount of nuclear MYBBP1a
and increased the amount of cytoplasmic MYBBP1a, whereas
transfection with F376del, which does not interact with MYBBP1a,
did not alter the amounts of nuclear and cytoplasmic MYBBP1a
[Fig. 2(B), (C)]. IL-1b treatment for 30 min decreased nuclear
amounts of MYBBP1a and increased cytoplasmic amounts of
MYBBP1a in WT and ank/ank cells [Fig. 2(B), (C)]. These ﬁndings
suggest that the ANK/MYBBP1a interaction prevents MYBBP1a
nuclear translocation and that the loss of this interaction results in
increased amounts of nuclear MYBBP1a.
Loss of ANK function resulted in decreased SPHK activity
SPHK activity was markedly increased in WT articular chon-
drocytes after treatment with IL-1b for 15 min compared to the
activity in vehicle-treatedWTcells [Fig. 3(A)]. Contrary, the increase
in SPHK activity was markedly reduced in IL-1b-treated ank/ank
chondrocytes compared to IL-1b-treated WT cells [Fig. 3(A)].
Transfection with ank and F376del, which bind to SPHK1 resulted
in increased SPHK1 activity in IL-1b-treated ank/ank chondrocytes
to levels similar to IL-1b-treated WT chondrocytes, whereas trans-
fectionwith P5L, which does not bind to SPHK1 resulted in a similar
SPHK activity as in IL-1b-treated empty vector-transfected
ank/ank chondrocytes [Fig. 3(A)]. Analysis of plasma membrane
fractions with antibodies speciﬁc to the active phosphorylated form
of SPHK1 revealed that IL-1b treatment resulted in a marked in-
crease of phosphorylated SPHK1 in WT chondrocytes; the increase
of phosphorylated SPHK1 was markedly reduced in IL-1b-treated
ank/ank chondrocytes compared to IL-1b-treated WT chondrocytes
[Fig. 3(B), (C)]. These ﬁndings show that ANK/SPHK1 interaction
increases SPHK activity in IL-1b-treated chondrocytes and that the
loss of this interaction results in decreased SPHK1 activity.
ANK stimulates NF-kB activity
Since the N-terminal region of ANK interacts with SPHK1 and
the C-terminal loop of ANK interacts with MYBBP1a, and both
MYBBP1a and SPHK1 regulate NF-kB activity16e18, we determined
how the interactions of ANK with both proteins affect NF-kB ac-
tivity. We transfected WT chondrocytes with ank EV and ank/ank
chondrocytes with ank, P5L or F376del EV and co-transfected these
cells with an NF-kB-speciﬁc luciferase reporter construct. After
serum-starvation for 24 h, cells were cultured for 6 h in the absence
or presence of IL-1b. Luciferase activity from the NF-kB luciferase
reporter was markedly increased in empty vector-transfected WT
chondrocytes after IL-1b treatment compared to vehicle-treated,
empty vector-transfected WT cells [Fig. 4]. Luciferase activity
from the NF-kB luciferase reporter was also increased in IL-1b-
treated, empty vector-transfected ank/ank chondrocytes; this in-
crease, however, was markedly less compared to IL-1b-treated WT
cells [Fig. 4]. Overexpression of ANK in WT mouse articular chon-
drocytes resulted in a further increase of NF-kB activity in the
presence of IL-1b compared to empty vector-transfected, IL-1b-
treated WT cells [Fig. 4]. Transfection of ank/ank chondrocytes withthe ank EV rescued NF-kB activity to levels similar to WT cells
overexpressing ANK. Contrary, transfection of ank/ank chon-
drocytes with the P5L or F376del EV resulted in less increases in
luciferase activity after IL-1b treatment compared to ank EV-
transfected, IL-1b-treated ank/ank cells [Fig. 4]. These ﬁndings show
that both interactions (ANK/MYBBP1a and ANK/SPHK1) contribute
to ANK-mediated stimulation of NF-kB activity and that the loss of
ANK/SPHK1 or ANK/MYBBP1a interaction results in reduced NF-kB
activity in IL-1b-treated chondrocytes.
To conﬁrm above ﬁndings and determine whether decreased
SPHK1 activity in IL-1b-treated ank/ank chondrocytes results in
reduced nuclear amounts of the p65 subunit of the NF-kB complex,
we analyzed nuclear and cytoplasmic cell fractions by immuno-
blotting using p65-speciﬁc antibodies. The amount of nuclear p65
was markedly reduced in IL-1b-treated ank/ank chondrocytes
compared to IL-1b-treated WT cells, whereas the amount of cyto-
plasmic p65 was increased in IL-1b-treated ank/ank chondrocytes
compared to IL-1b-treated WT cells [Fig. 5(A), (B)]. The SPHK in-
hibitor, SKI-II reduced the amount of nuclear p65 and increased the
amount of cytoplasmic p65 in IL-1b-treated WT chondrocytes but
not in IL-1b-treated ank/ank chondrocytes [Fig. 5(A), (B)]. These
ﬁndings show that the ANK/SPHK1 interaction results in increased
SPHK1 activity and nuclear translocation of p65 in IL-1b-treated
chondrocytes.
The effect of loss of ANK function on the expression of catabolic
markers and cartilage degradation after IL-1b treatment
mRNA levels of catabolic marker genes, including ADAMTS-5,
Cox-2, IL-6, iNOS and MMP-13, which are regulated by NF-kB and
play major roles in OA pathology11, increased in WT and ank/ank
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Fig. 5. A: IB analysis of the nuclear (N) and cytoplasmic (C) fractions isolated fromWTand ank/ank chondrocytes treatedwith SPHK inhibitor (SKI-II) and IL-1bwith antibodies speciﬁc
for p65. SKI-II treatment was started 1 h before IL-1b treatment followed by IL-1b treatment for 15 min. Vehicle-treated WT cells are shown in lane 1, while vehicle-treated ank/ank
cells are shown in lane 3. The blot was also analyzed with antibodies speciﬁc for b-actin, a cytoplasmic protein, and lamin B, a nuclear protein, to control for equal loading in each
fraction. Representative blots of three separate experiments with similar results are shown. B: Quantitative analysis of band intensity was measured using VisionWorksLS software.
Data were normalized to the band intensities of lamin B or b-actin, respectively, and the normalized values from the vehicle-treatedWTcells (IL-1,SKI-II) were set as 1. The results
represent the meanwith 95% CI (normalized band intensities from three independent blots using three different cell cultures for theWTand the ank/ank group; onemouse per group
was used to isolate cells for one culture). Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. P value means comparing with indicated group.
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vehicle-treated WT or ank/ank chondrocytes [Fig. 6]. However, the
increases of the mRNA levels of these catabolic markers in IL-1b-
treated ank/ank chondrocytes were considerably reduced
compared to IL-1b-treated WT cells (51% reduction in ADAMTS-5,
32% reduction in Cox-2, 41% reduction in IL-6, 40% reduction in
iNOS, 43% reduction in MMP-13 mRNA levels; Fig. 6).
To determine the role of ANK in IL-1b-mediated articular carti-
lage degradation, femoral heads isolated from 18-week-old ank/ank
mice and WT littermates were cultured in the absence or presence
of IL-1b for 4 days. Proteoglycan loss as determined by the loss
of safranin O staining was markedly reduced in IL-1b-treated
ank/ank femoral heads compared to IL-1b-treated WT femoral
heads [Fig. 7(A)]. Furthermore, decreasedMMP-13 immunostaining
was evident in IL-1b-treated ank/ank femoral heads compared to IL-
1b-treated WT femoral heads [Fig. 7(A)]. Quantiﬁcation of safranin
O staining after IL-1b treatment using a previously described
scoring system19 revealed a marked reduction in the loss of pro-
teoglycans in IL-1b-treated ank/ank femoral heads compared to IL-
1b-treated WT femoral heads [Fig. 7(B)]. Vehicle-treated WT and
ank/ank femoral heads showed no loss of safranin O staining and
no MMP-13 immunopositive cells [Fig. 7(A)]. These ﬁndings
demonstrate that loss of ANK function results in reduced mRNAlevels of catabolic markers and proteoglycan loss in IL-1b-treated
chondrocytes.
Discussion
The ﬁndings of this study demonstrate that ANK interacts with
MYBBP1a and SPHK1 and that these interactions stimulate NF-kB
activity. Consequently, lack of ANK function resulted in decreased
mRNA levels of catabolic genes, including ADAMTS-5, Cox-2, IL-6,
iNOS and MMP-13, and decreased proteoglycan loss and MMP-13
immunostaining in IL-1b-treated ank/ank chondrocytes or
femoral head explants compared to IL-1b-treatedWTchondrocytes
or femoral head explants.
Our ﬁndings show that MYBBP1a binds to a region of ANK that
contains most of the CMD mutations, including the F376del mu-
tation, whereas SPHK1 interacts with the N-terminal region that
contains many of the chondrocalcinosis mutations, including the
P5L mutation8,9,15,20. Since MYBBP1a and SPHK1 are cytoplasmic
proteins, our ﬁndings support previous predictions suggesting that
these regions of ANK are located in the cytoplasm10.
MYBBP1a is a cytoplasmic protein that shuttles into the nucleus
where it represses NF-kB16. Our ﬁndings showing that the lack of
ANKresulted in increased amountsof nuclearMYBBP1a suggest that
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Fig. 6. mRNA levels of catabolic (ADAMTS-5, Cox-2, IL-6, iNOS and MMP-13) in WT and ank/ank chondrocytes treated with vehicle (IL-1) or IL-1b (þIL-1) for 6 h mRNA levels were
determined by real time PCR using SYBR Green and normalized to 18S RNA. Each PCR reactionwas run in triplicates. The results represent the meanwith 95% CI (three different RNA
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T. Minashima et al. / Osteoarthritis and Cartilage 22 (2014) 852e861 859MYBBP1a interaction with ANK prevents MYBBP1a’s translocation
to the nucleus. In addition, the loss of ANK/SPHK1 interaction
markedly reduced SPHK activity in IL-1b-treated chondrocytes.
Consequently, transfection with full-length ank rescued the
amounts of nuclear MYBBP1a and SPHK1 activity in IL-1b-treated
ank/ank chondrocytes. Contrary, transfection with P5L, which does
not bind to SPHK1, only rescued the amounts of nuclear MYBBP1a,
while transfection with F376del, which does not interact withSafranin O
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the M48T chondrocalcinosis ANK mutation interrupted the inter-
action of ANK with the sodium/phosphate co-transporter Pit-121.
Taken together these ﬁndings suggest that the interactions of ANK
with other proteins are altered or lost in chondrocalcinosis or CMD
mutations of ANK, and these altered or lost interactions may
contribute to the disease phenotypes besides the altered PPi trans-
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the SPHK1/S1P axis also plays an essential role in NF-kB activa-
tion16,17,22,23. Loss of MYBBP1a/ANK and SPHK1/ANK interactions
resulted in decreased NF-kB activity and ultimately decreased
expression of catabolic markers, including ADAMTS-5, Cox-2, IL-6,
iNOS and MMP-13 in IL-1b-treated ank/ank articular chon-
drocytes. Transfection with the P5L mutant ANK or the F376del
mutant ANK, which restored the MYBBP1a/ANK or ANK/SPHK1
interaction, respectively, only partially rescued NF-kB activity in IL-
1b-treated ank/ank chondrocytes, suggesting that both interactions
play major roles in NF-kB activation and ultimately the regulation
of catabolic events in articular chondrocytes.
Lack of ANK function resulted in decreased SPHK1 activity and
ultimately decreased sphingosine 1-phosphate (S1P), the actual
modulator of SPHK activity affecting cellular function22e24. A pre-
vious study by Stradner et al. has shown that S1P treatment
resulted in reduced ADAMTS-4, iNOS and MMP-13 expression
levels in IL-1b-treated articular chondrocytes25. Contrary, our study
shows that decreased SPHK activity together with increased
amounts of nuclear MYBBP1a in IL-1b-treated ank/ank chon-
drocytes resulted in decreased mRNA levels of catabolic markers,
including ADAMTS-5, Cox-2, IL-6, iNOS and MMP-13. Whereas the
study by Stradner et al. only determined the effects of extracellular
S1P on chondrocytes25, our study determined the effects of SPHK1
activity and ultimately intracellularly generated S1P on articular
chondrocytes. Intracellularly generated S1P can affect cell function
by being transported to the extracellular milieu, where it acts via
speciﬁc receptors, and/or intracellularly via directly affecting
various signaling pathways, including NF-kB22,24. Future studies
must determine the exact mechanisms of how S1P affects articular
chondrocyte functions during physiology and disease.
In conclusion, this study shows that ANK interacts via N-ter-
minal and C-terminal cytoplasmic regions with SPHK1 and
MYBBP1a, respectively. The ANK/MYBBP1a interaction results in
the inhibition of the nuclear translocation of MYBBP1a. Nuclear
MYBBP1a acts as a co-repressor of NF-kB transcriptional activity16.
The ANK/SPHK1 interaction is a major regulator of SPHK1 activity.
Both interactions stimulate NF-kB activity and ultimately catabolic
events in IL-1b-treated articular chondrocytes. Since IL-1b and NF-
kB play major roles in OA pathogenesis11,26, our ﬁndings suggest
that increased ANK expression in OA cartilage may be a major
contributor to cartilage destruction. Future experiments are needed
to fully understand the mechanisms of the interactions between
ANK, MYBBP1a and SPHK1 in OA pathology and develop strategies
to interfere with these interactions as a potential novel therapy for
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